Immunotherapy with immune check point inhibitors (ICIs) is currently available for all programmed death 1 (PD1)/programmed death ligand 1 (PDL1) positive NSCLC subtypes, while targeted therapies are limited to patients with lung adenocarcinoma harboring specific genetic alterations like EGFR, BRAF, and MET mutations, as well as ALK, ROS1, and RET rearrangements or NRTK1/2/3 gene fusions [5]. This evidence concerns the gene MET and non-small cell lung carcinoma.